In the era when various treatment agents for advanced-stage prostate cancer are available, it is important to investigate overall survival for metastatic prostate cancer treated with step-up hormonal treatment as a reference against new treatment regimens, including antitumor agents and/or new hormonal derivatives, and it is desirable to explore pretreatment, biopsy-related and post-treatment prognostic factors to establish tailor-made treatment strategies.
Introduction
The incidence of very-advanced-stage prostate cancer and mortality rate of prostate cancer have decreased in western countries where screening for prostate cancer has spread. 1, 2 Alternatively, in most countries where the exposure rate of PSA screening is still low, the incidence of prostate cancer has continued to increase, as has its mortality. In Japan, where the exposure rate of PSA screening is estimated to be B5%, 3 the number of deaths because of prostate cancer has increased since 1970 and was estimated to be 10 036 in 2009. 4 The percentage of prostate cancer with distant metastases was still high at B20% in Japan. 5 The management of prostate cancer patients with distant disease may be a serious problem, particularly in many countries where PSA screening is not very common, and also for men living in the United States and Western Europe but detected outside the screening system.
Randomized controlled trials in patients with hormonerefractory prostate cancer 6, 7 have shown that 3-weekly docetaxel-based chemotherapy has modest but significant superiority to a weekly regimen or mitoxantrone. Therefore, many patients have been treated with docetaxel for recurrent disease after any stage of hormonal therapy. However, the optimal indication of 3-weekly docetaxelbased chemotherapy has not been identified. Furthermore, many new derivatives including antiandrogen (MDV3100), 8 steroid 17-a-hydroxylase and 17,20-lyase (P450C17) inhibitor (abiraterone acetate), 9 17,20-lyase inhibitor (TAK-700) 10 and a patient-specific therapeutic cancer vaccine for prostate cancer (Sipuleucel-T) 11 may have some role in treatment of castration-resistant prostate cancer. 12 It is important to investigate outcomes and prognostic factors of very-advanced-stage prostate cancer treated by classical step-up hormonal treatment as references for evaluating newly developed strategies. Alternatively, if it were possible to establish significant surrogate markers to predict the prognosis of patients with metastatic prostate cancer who have been treated with step-up standard hormonal treatments, we would be able to propose more effective treatment strategies, including continuing various standard hormonal agents, changing to docetaxel-based chemotherapy, trying newly developed hormonal derivatives or enrolling in clinical trials with more accurate scheduling.
In the present study, we aimed to establish predictive clinicopathological factors and to predict individual outcomes of conventional step-up hormonal therapies for very-advanced-stage prostate cancer, as a reference against new treatment regimens, including antitumor agents and/or new hormonal derivatives. The impact of pretreatment clinical factors, local pathological tumor volume/grade indexes in biopsy specimens and PSA response following first-, second-and third-line hormonal therapy on overall survival were investigated in patients with metastatic prostate cancer who had never been treated with docetaxel-based chemotherapy for castration-resistant prostate cancer.
Materials and methods
We enrolled 94 consecutive patients with metastatic prostate cancer at initial diagnosis in Gunma University Hospital between January 1992 and December 2002. Of the patients, 87 (92.6%) had bone metastases, 4 (4.3%) had lung metastases and 3 (3.2%) had paraaortic lymph node metastases. Median follow-up was 38.8 months (range: 1.3-174.8 months). The clinicopathological features are indicated in Table 1 . Pretreatment clinical findings including age, serum PSA, testosterone, alkaline phosphatase (ALP), clinical T category on digital rectal examination (DRE) and extension of disease (EOD) 13 were investigated for their predictive value on outcome. EOD is a semiquantitative grading system based on extension of bone metastases observed on bone scanning and is scored from 0 to 4. All EOD scores were reviewed by one researcher (SM). Furthermore, the impact of local pathological findings including percentage of positive biopsy cores, tumor volume index, Gleason score (GS), primary Gleason grade, primary Gleason grade 5 (G5) volume index, G5 volume index and GS9-10 volume index in biopsy specimens and post-treatment PSA nadir status following first-, second-and third-line hormonal therapy on survival was also investigated.
A total of 79 cases were biopsied before initiating hormonal therapy, and 15 were treated with hormonal therapy before prostate biopsy because of their severe disease status. Systematic biopsies were done via transrectal ultrasonography guidance, and six cores were taken from the peripheral zone (in some cases; six from the peripheral zone and additional two cores from the transition zone). Additional biopsy cores were taken if a hypoechoic area or nodule did not exist on the route of systematic biopsies. All GSs were reviewed by one urological pathologist (KS) at Gunma University according to the criteria proposed by the 2005 International Society of Urological Pathology consensus conference on Gleason grading of prostatic carcinoma.
14 The percentages of any tumors, primary G5, secondary G5 and GS9-10 in each biopsy specimen were scored at 10% intervals (for example, 0% as a 0% score, 1-10% as a 10% score and 11-20% as a 20% score). Details of the biopsy and GS index are shown in Figure 1 .
All cases underwent a bone scan, abdominal and pelvic computed tomography (CT) and chest X-ray for clinical staging. During follow-up, PSA was measured once every 1-3 months; DRE was done every 3 months; and CT and bone scanning were conducted once every 2 years regardless of clinical progression, in patients with any specific symptoms that may have been related to cancer progression. The fundamental treatment strategies for step-up hormonal and palliative therapy are shown in Figure 2 . Initial hormonal therapy was luteinizing hormone-releasing hormone (LHRH) agonist monotherapy with a short-term steroidal antiandrogen to prevent flare-up phenomenon. Combined androgen blockade (CAB) using a nonsteroidal antiandrogen with an LHRH agonist was not given as initial hormonal therapy, but was given for some cases as salvage therapy following an increase in PSA during LHRH agonist monotherapy. First-line hormonal therapy was defined not only as LHRH agonist monotherapy but also for CAB done in an initial and salvage setting. First-, second-and third-nadir PSA were defined as the lowest PSA levels during first-, second-and third-line hormonal therapy, respectively. Hormonal therapy was usually stepped up to the subsequent treatment strategy indicated in Figure 2 . Treatment step-up should be considered in cases with PSA increased 410 ng ml À1 after decreasing PSA nadir o10 ng ml -1 ; cases with continuous PSA increase at each stage of hormonal treatment; and cases with any objective or subjective clinical progression regardless of PSA levels. A total of 10 (10.6%) patients were treated with docetaxel-based chemotherapy following third-line hormonal treatment at 71.1 months after starting first-line hormonal therapy. The date of starting chemotherapy was considered as the last date of observation. Therefore, no data on patients who were treated with docetaxel-based chemotherapy for castration-resistant status were included during the investigation. Individual causes of death were judged and recorded by experienced clinical urologists in Gunma University Hospital working in inpatient clinics, who were not associated with the present study.
The present study was approved by the ethics committee of Gunma University Graduate School of Medicine .
All statistical analyses were done using Dr SPSS II (SPSS, Chicago, IL, USA) or Stat Flex (Ver. 5.0; Arttech, Osaka, Japan). Overall survival was estimated by KaplanMeier analysis. Age, PSA, serum testosterone, ALP, DRE findings and EOD were scored as pretreatment factors; pathological factors including biopsy GS and original GS indices ( Figure 1 ) as well as nadir PSA levels after first-, second-and third-line hormonal treatment as posttreatment factors were investigated for their relations with all causes of death. The cutoffs of the above clinicopathological factors for Kaplan-Meier analyses were explored by separating patients in binary, tertiary or quartiles to establish more significant and meticulous separation. If two adjacent subgroups were considered to have an equal predictive value, they were combined into one subgroup. Cox proportional hazard model was used to determine independent significant predictive factors. To explore the independent surrogate factors to predict all causes of death, stepwise multiple regression analysis was performed using forward selection. In the stepwise multiple regression analysis, all clinicopathological factors, excluding pretreatment PSA and PSA nadir, were handled as categorical variables. Pretreatment PSA levels were converted to log 10 PSA, and PSA nadir was converted to log 10 (PSA nadir þ 1) to avoid log transforming a PSA nadir of 0, and were handled as continuous variables. 
Results
Concerning first-line hormonal therapy, 84 (89.4%) patients were treated only with LHRH agonist monotherapy. Only one (1.1%) patient underwent CAB using a nonsteroidal antiandrogen with LHRH agonist as initial treatment. Nine (9.6%) patients received an additional nonsteroidal antiandrogen as salvage therapy because of PSA increase during LHRH agonist monotherapy. PSA before second-line hormonal treatment was a median 48.6 ng ml -1 (range: 0.3-1537 ng ml -1 ). Palliative radiotherapy to the prostate and/or bone was done in 45 (47.9%) patients.
A total of 41 (43.6%) patients died during observation; 31 (75.6%) died because of prostate cancer progression; 3 (7.3%) died from other diseases with recurrence of prostate cancer during first-or second-line hormonal treatment; and 7 (17.1%) died of other diseases without PSA recurrence during the first (7.3%), second (7.3%) or third (2.4%) hormonal treatment. The overall survival of 94 patients was 72.4% at 3 years and 62.5% at 5 years. Tables 2-4 show 3-and 5-year overall survival stratified by various pretreatment, pathological and post-treatment factors. Concerning pretreatment factors, PSA levels p100 ng ml -1 , ALP within the double of standard upper limit (that is, p440 IU l -1 ), T1c-T3 on DRE and EOD score 0-3 showed a significantly better prognosis compared with those with an alternative finding in each corresponding factor (Table 2) . Concerning pathological factors, GS and primary Gleason grade could differentiate patients with a significantly better prognosis from those with a worse prognosis. However, new pathological indices, particularly G5 volume index in biopsy specimens, enabled more meticulous separation of risk group and had more significant discriminative power among patients with better prognosis and those with worse prognosis (Table 3) . Concerning factors related to treatment response, tertiary divided nadir PSA cutoffs during first-and second-line hormonal therapy could discriminate patients with better prognosis from those with worse prognosis. Furthermore, the number of patients at risk was small, but PSA response during third-line hormonal treatment could significantly affect overall survival (Table 4) . Table 5 shows significant pretreatment, pathological and post-treatment factors that affected overall survival after starting second-line hormonal treatment. During median follow-up of 22.5 months, overall survival in 66 patients was 56.6% and 42.7% at 3 and 5 years, respectively, after starting second-line hormonal treatment. Many pretreatment clinicopathological factors and nadir PSA levels after first-and second-line hormonal treatment could still be predictive factors that were significantly related to overall survival after starting second-line hormonal treatment. Table 6 shows independent factors to predict overall survival determined by multivariate Cox proportional hazard model. Candidates for stepwise multiple regression analysis were pretreatment factors and G5 volume index as a representative of pathological factors and first-and second-nadir PSA as representatives of posttreatment factors, which were revealed as significant predictive factors for overall survival by Kaplan-Meier analysis. When second-nadir PSA was excluded from the model, clinical T category on DRE findings, first-nadir PSA, G5 volume index and ALP were independent Figure 2 Fundamental androgen deprivation and palliative treatment strategies in Gunma University Hospital for metastatic prostate cancer before introducing docetaxel-based chemotherapy for castration-resistant prostate cancer.
Predictive factors of metastatic prostate cancer S Miyamoto et al Predictive factors of metastatic prostate cancer S Miyamoto et al Predictive factors of metastatic prostate cancer S Miyamoto et al factors, which affected overall survival for all patients with metastatic disease. When second-nadir PSA was included in the model, second-nadir PSA, G5 volume index and ALP were independent factors affecting overall survival. In 66 patients who were followed after starting second-line hormonal treatment, second-nadir PSA independently and strongly affected and G5 volume index showed a nearly significant potential to predict overall survival after starting second-line hormonal treatment. Figures 3a and b show overall survival estimated by Kaplan-Meier analysis according to the first-and secondnadir PSA. Both first-and second-nadir PSA showed significant discriminative power on overall survival during step-up hormonal treatment. Figures 3c and d show overall survival after starting second-line hormonal treatment. According to univariate analysis, first-nadir PSA still had predictive power even on overall survival after starting second-line hormonal treatment. Secondnadir PSA could differentiate patients with better prognosis from those with worse prognosis in an independent manner. The long-term prognosis of good responders by first-and second-line hormonal treatment would be excellent even in patients with metastatic disease.
Discussion
We clearly showed that clinical outcome was variable even in patients with metastatic disease. We also demonstrated that well-known pretreatment factors, including PSA levels, ALP, EOD score and biopsy GS, [15] [16] [17] as well as newly developed pathological factors, including G5 volume index, primary G5 volume index and GS9-10 volume index, and post-treatment PSA status, including PSA nadir at any stage of hormonal therapy, could predict overall survival in patients with distant and nonregional lymph node metastases, by univariate analyses.
According to the multivariate Cox proportional hazard model, first-nadir PSA and ALP were independent predictive factors for overall survival. Furthermore, clinically and pathologically confirmed local tumor status (that is, G5 volume index in biopsy specimens and T category by DRE) were also independent predictive factors for overall survival, even in patients with metastatic disease at initial diagnosis. Classical possible predictive factors like pretreatment PSA and EOD scores did not affect overall survival in an independent manner. Calculation of G5 volume index in biopsy specimens may require some effort, but can give important information on prognosis for patients with very advanced disease. In patients treated with second-line hormonal therapy after having a second PSA nadir, treatment effectiveness was strongly related to overall survival regardless of the effects of first-line treatment.
Recently, it has been demonstrated that the percentage of G4 and G5 radical prostatectomy specimens is an important predictive factor for PSA recurrence after radical prostatectomy in patients with localized prostate cancer. 18 Alternatively, it is well known that GS in biopsy specimens may underestimate final pathology in radical prostatectomy specimens. The present study revealed that, even in patients with distant metastases at Table 4 Impact of PSA nadir following various stages of endocrine treatment on overall survival 
15.9%
First-nadir PSA is nadir PSA after initial androgen deprivation therapy; second-nadir PSA is nadir PSA nadir after second-line hormonal therapy; and third-nadir PSA is nadir PSA after third-line therapy.
Predictive factors of metastatic prostate cancer S Miyamoto et al Predictive factors of metastatic prostate cancer S Miyamoto et al initial diagnosis, G5 volume index in biopsy specimens could be independently more predictive of overall survival compared with simple percentage of positive biopsy cores and GS in biopsy specimens. It is suggested that patients with large high-grade prostate tumors may also have had high-grade lethal cancer cells in their metastatic sites. Therefore, it may be reasonable to conduct systematic biopsies and calculate the G5 volume index even in patients with metastatic prostate cancer. In contrast to localized prostate cancer, biopsy high Gleason grade tumor volume indices in patients with very advanced prostate cancer may be strongly related to high-grade cancer volume throughout the body. Some investigators have demonstrated the prognostic significance of nadir PSA after androgen deprivation therapy for locally advanced and/or metastatic prostate cancer in terms of survival or progression to androgenindependent status. [19] [20] [21] [22] [23] [24] The EORTC 30892 study has demonstrated that PSA response at 6 months after androgen deprivation therapy for metastatic prostate cancer can predict survival. 19 Median overall survival rates were 6.4, 3.8 and 2.3 years in patients with nadir PSA p1, 1-10 and 410 ng ml -1 , respectively. In the present study, it was interesting to note that both first and second PSA nadir independently predicted overall survival. Regardless of the response to first-line hormonal therapy, patients with a good response to second-line treatment can have excellent overall survival. Furthermore, in the present study, one patient treated with First-nadir PSA is nadir PSA after initial androgen deprivation therapy, and second-nadir PSA is nadir PSA after second-line hormonal therapy. In the stepwise multiple regression analysis for overall survival after secondline hormonal treatment, 0.0-0.5, 0.6-25.0 and 25.1-100 on G5 volume index are coded by 1, 2 and 3, respectively. log 10 (first-nadir PSA+1) and log 10 (second-nadir PSA+1) were treated as continuous variables in the stepwise multiple regression analysis.
Predictive factors of metastatic prostate cancer S Miyamoto et al estrogen-derived agents died because of cardiac failure and intestine ileus at 2.9 months after starting second-line hormonal treatment with diethylstilbestrol diphosphate.
Recently, the impact on disease outcome of PSA kinetics during PSA recurrence following androgen deprivation therapy has been investigated. [25] [26] [27] In overview, a shorter PSA doubling time, higher PSA velocity or PSA progression could predict poor survival. Hussain et al. 27 have investigated a significant definition and cutoffs of PSA progression, which may relate to overall survival, during hormonal therapy and chemotherapy in hormone-sensitive prostate cancer and castrationresistant prostate cancer, respectively. They demonstrated that a patient with X25% increase and absolute increase of at least 2 or 5 ng ml À1 in PSA progression within 7 months after starting hormonal treatment had significantly poor overall survival at the hormone-sensitive stage, and the above definition of PSA progression could be a surrogate end point for clinical trials. In a clinical setting, it may be better to know outcomes at earlier stages of treatment. Therefore, the pretreatment factors revealed in the present study may be helpful in choosing appropriate treatment without unacceptable delays. The G5 volume index may provide useful information on when to start and how to set subsequent treatment strategies including docetaxel-based chemotherapy in patients with metastatic prostate cancer.
In the present study, LHRH agonist monotherapy was mainly selected as an initial hormonal therapy. If PSA increases during LHRH agonist monotherapy, salvage nonsteroidal antiandrogen therapy is sometimes added to LHRH agonist. Some recent studies have shown better outcomes in patients treated with CAB compared with LHRH agonist monotherapy. [28] [29] [30] However, a metaanalysis and randomized placebo-controlled clinical trial have revealed that the difference between LHRH agonist and CAB was only of a few percentage or nothing. 31, 32 Therefore, the initial treatment strategy within the present step-up for hormonal therapy may be reasonable in clinical settings. In fact, although the present series did not use CAB as the initial hormonal therapy for most cases, the 5-year overall survival could be above average at 63%. The careful administration of second-and thirdline hormonal therapy may result in relatively good outcomes. Treatment strategy for patients with very advanced disease may be reasonable in terms of having good treatment outcomes and also reducing cost.
In the present study, there were some limitations in the treatment strategy. First, estrogen-derived agents may cause severe complications, such as venous thrombosis. Only one patient died because of severe cardiac disease. However, although Asian men have a lower prevalence of obesity than Americans, anticoagulants should be added during treatment with estrogen derivatives. However, patients with metabolic syndrome and potential cardiovascular problems might have a high risk of developing venous thrombosis with estrogen derivatives. Therefore, potentially safe and effective antiandrogenic agents like MDV3100 may be more acceptable and could become mainstream treatment after PSA recurrence following first-line hormonal therapy with LHRH agonist.
Second, the present treatment strategy did not include effective chemotherapy using docetaxel hydrate for hormone-refractory prostate cancer. 8, 9 Additionally, bisphosphonate was not available during the present study. However, some patients who showed a good response to first-and second-line hormonal therapy had 
Conclusions
It is important to know the outcomes and prognostic factors in patients with advanced-stage prostate cancer treated with step-up hormonal treatment for reference in an era when treatment strategies including docetaxelbased chemotherapy and newly developed antitumor or hormonal agents could be available. Even in patients with very-advanced-stage prostate cancer, systematic biopsy may provide useful information on overall survival. Patients with a high G5 volume index in biopsy specimens should be treated with chemotherapy or clinical trials in the early phase of treatment strategies. Furthermore, treatment response after first-and secondline hormonal therapy may be of equal value for predicting overall survival, and PSA nadir after second-line hormonal therapy could be independently important for predicting overall survival.
